Preliminary study on the safety and efficacy of epidural electrical stimulation for treating lower urinary tract dysfunctions after spinal cord injury.
Descrizione riassuntiva dello studio
There is no cure for bladder dysfunctions following spinal cord injury. Therefore, individuals with spinal cord injuries often have to use a catheter to empty their bladder. This can be uncomfortable and painful, and can also lead to infections. These individuals may also suffer from overactive bladder syndrome, which means they have a sudden urge to urinate and may experience urinary leakage. Recent studies have shown that electrical stimulation of the spinal cord may help improve bladder control. This technology was initially tested on animals. Preliminary results on bladder function have also been observed in a patient who received an electrical stimulator in the spinal cord region controlling leg movements. In this clinical trial, called ReeVoid, we will study the safety (safety) and efficacy of stimulation of the lower spinal cord region (sacral region) that controls the urinary system in 3 participants. This therapy consists of 2 neurostimulators and 2 electrode fields implanted on the back of the spinal cord. A neurostimulator is a small device that sends electrical impulses. An electrode field is a thin wire that carries electrical impulses to the spinal cord.
(BASEC)
Intervento studiato
Participation in this study will last 10 months, including 8 weeks of intense participation and 8 months of a lighter follow-up phase. The study includes 6 different phases. Each phase includes different types of sessions and assessments.
1. Eligibility (up to 1 week): At CHUV, the clinical team will check the general health status and the spinal cord injury. They will ask questions about medical history and medications taken. We will also examine how the spinal cord injury affects the participant and bladder function. We will perform certain examinations such as medical imaging and clinical assessments.
2. Referral (up to 2 weeks): Once eligibility is confirmed, we will conduct some tests and ask questions to understand the current bladder function. This serves as a starting point for comparison. The participant will also receive a special mobile application to track these bladder habits on a phone or tablet during these two weeks, in the form of a voiding diary. This will help us detect any changes in bladder function throughout the study.
3. Surgical procedure: The participant will undergo surgery under general anesthesia for the implantation of 2 electrode fields on the spinal cord and 2 neurostimulators in the abdominal region. The procedure will take place at CHUV.
4. Configuration phase (up to 4 weeks): The researchers will test different stimulation parameters on the medical device to see what works best to improve your bladder control, both when the participant needs to empty their bladder (voiding) and when they feel the urge to have a bowel movement (calming). They will adjust the parameters so that the therapy works best. Once the investigator physician has decided that the therapy is safe, participants will be able to use it at home.
5. Follow-up phase (up to 8 months). Participants will be able to use the therapy in their daily lives until the end of the study, if approved by the investigator physician. The research team may need to conduct additional configuration sessions to adjust the parameters of the medical device.
6. End of the study. The medical device may be explanted, inactivated, or kept active for use after the study ends. Participants will continue to use it only if the investigator physician deems it safe and beneficial for them.
Clinical assessments and questionnaires: Throughout the clinical trial, participants will need to undergo clinical assessments at CHUV: before the operation, and at 3 different times after the operation. They will also fill out questionnaires and keep an electronic voiding diary with information about bladder function at home.
(BASEC)
Malattie studiate
Lower urinary tract dysfunctions after spinal cord injury
(BASEC)
1. 18 years or older ; 2. Must provide and sign the informed consent form prior to any study-related procedures ; 3. Spinal cord injury level above T11 (inclusive) ; 4. Spinal cord injury classified as ASIA B, C, or D ; 5. Injury age ≥ 6 months ; 6. Confirmed vesico-sphincter disorders during urodynamic assessment (NDO, DSD) ; 7. Ineffectiveness or intolerance of ongoing treatments ; 8. Use of intermittent urinary catheterization ; 9. Stable medical, physical, and psychological conditions according to investigators ; 10. Able to understand and interact with the study team in French or English ; 11. Agree to comply in good faith with all study conditions and to attend all scheduled appointments ; (BASEC)
Criteri di esclusione
1. Injection of botulinum toxin non-bladder and bladder in the last 6 months ; 2. Presence of non-pharmacological treatments for lower urinary tract dysfunction (e.g., sacral nerve stimulation) ; 3. Possession or need for a suprapubic catheter or indwelling catheter ; 4. Presence of dilation of the upper urinary tract or bladder or kidney stones ; 5. Presence of urethral stricture or benign prostatic hyperplasia ; 6. Presence of pressure sores; 7. Previous surgery of the lower urinary tract ; 8. Presence of autonomic dysreflexia during a urodynamic test ; 9. Recurrent and symptomatic urinary infections (more than 3 per year) ; 10. Presence of an intrathecal baclofen pump ; 11. Conditions that would increase morbidity and mortality of spinal surgery ; 12. Other clinically significant concomitant conditions (e.g., syringomyelia, bladder cancer, renal failure, liver dysfunction, cardiovascular disease, etc.) ; 13. Contraindication to antiplatelet or anticoagulant therapy during the perioperative period ; 14. Presence of pacemakers ; 15. Other conditions that, in the opinion of the investigators, would render the subject unable to participate in the tests ; 16. Pregnant women (pregnancy test mandatory for women of childbearing age) or breastfeeding ; 17. Absence of safe contraception for women of childbearing age ; 18. Intention to become pregnant during the study duration ; 19. Inability to follow study procedures, e.g., due to language issues, mental illness, psychological disorders, or dementia of the participant ; 20. Participation in another study with an experimental drug or device within 30 days prior to and during this study ; 21. Condition requiring magnetic resonance imaging (MRI). 22. It must not be the investigator themselves, family members, employees, or other dependent persons. (BASEC)
Luogo dello studio
Losanna
(BASEC)
Sponsor
Ecole Polytechnique Fédérale Lausanne (EPFL)
(BASEC)
Contatto per ulteriori informazioni sullo studio
Persona di contatto in Svizzera
Jocelyne Bloch
+41 79 556 29 51
neurorestore.studies@clutterchuv.chCentre Hospitalier Universitaire Vaudois
(BASEC)
Informazioni scientifiche
non disponibile
Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)
Commissione d'etica Vaud
(BASEC)
Data di approvazione del comitato etico
19.02.2025
(BASEC)
ID di studio ICTRP
non disponibile
Titolo ufficiale (approvato dal comitato etico)
Study on preliminary safety and efficacy of epidural electrical stimulation to manage lower urinary tract dysfunction after spinal cord injury. (BASEC)
Titolo accademico
non disponibile
Titolo pubblico
non disponibile
Malattie studiate
non disponibile
Intervento studiato
non disponibile
Tipo di studio
non disponibile
Disegno dello studio
non disponibile
Criteri di inclusione/esclusione
non disponibile
non disponibile
Endpoint primari e secondari
non disponibile
non disponibile
Data di registrazione
non disponibile
Inclusione del primo partecipante
non disponibile
Sponsor secondari
non disponibile
Contatti aggiuntivi
non disponibile
ID secondari
non disponibile
Risultati-Dati individuali dei partecipanti
non disponibile
Ulteriori informazioni sullo studio
non disponibile
Risultati dello studio
Riepilogo dei risultati
non disponibile
Link ai risultati nel registro primario
non disponibile